Advances in molecular biology have opened promising avenues, such as targeting vascular endothelial growth factor (VEGF) and promoting lymphangiogenesis to improve lymphatic function and mitigate HF-associated complications [19]. The gene discussed is VEGFA; the disease is hydrops fetalis.